PROTEONOMIX, INC.'s (PROT) CEO to Present at Investor Summit 2012 Sponsored by Merriman Capital in New York on February 1, 20...
27 Janeiro 2012 - 11:20AM
Marketwired
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on
developing therapeutics based upon the use of human cells and their
derivatives, announced today that it will be presenting at the
Investor Summit 2012 on February 1, 2012, sponsored by Merriman
Capital at the Intercontinental Time Square Hotel in New York City.
Michael Cohen, President of the Company, stated: "We thank
Merriman Capital for the opportunity address the investment
community regarding the Company's UMK 121 technology. The Company
will address the use of the technology in the emerging markets,
particularly in Africa where large numbers of cases of severe
cirrhosis and accompanying End Stage Liver Disease exist."
Mr. Cohen continued, "Our UMK-121 pharmaceutical therapy is
advancing toward its first clinical trial in ESLD ("End Stage Liver
Disease") patients. In addition we intend to highlight other parts
of our company of interest to the investment community including
our Proteoderm cosmeceutical subsidiary and StromaCel."
About Proteonomix, Inc.: Proteonomix is a biotechnology company
focused on developing therapeutics based upon the use of human
cells and their derivatives. The Proteonomix Family of companies
includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR
Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has
developed an anti-aging line of skin care products. StromaCel, Inc.
develops therapeutic modalities for the treatment of Cardiovascular
Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating
subsidiary. Proteonomix Regenerative Translational Medicine
Institute, Inc. ("PRTMI") intends to focus on the translation of
promising research in stem cell biology and cellular therapy to
clinical applications of regenerative medicine. Proteonomix intends
to create and dedicate a subsidiary to each of its technologies.
Please also visit http://www.proteonomix.com/,
http://www.proteoderm.com/, http://www.otcqb.com/ and
http://www.sec.gov/.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Proteonomix, Inc. Michael Cohen CEO Phone:
+1-973-544-6116 Email: Email Contact
Proteonomix (CE) (USOTC:PROT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Proteonomix (CE) (USOTC:PROT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Proteonomix Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Proteonomix